A Phase 2 interventional study of Enzalutamide and Leuprolide in Prostate Cancer, sponsored by Pfizer. Completed at 4 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 63rd largest by enrollment, is one of 5 that started in 2012, is one of 65 in phase 2, and was the 11th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Prostatic Neoplasms by Pfizer: 3 open now, 8 under way, 5 of them phase 3. Of 33 finished, 28 (85%) have results posted.
Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 25th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2012, is one of 10 in phase 2, and was the 15th registered.
Pfizer’s Prostatic Neoplasms studies by the year they started, since 1998.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Pfizer’s 42 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enzalutamide 160 mg, orally, once daily
Drug: Enzalutamide
Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
Drug: Enzalutamide · Drug: Leuprolide · Drug: Dutasteride
Also known as: MDV3100
Pathologic Complete Response Rate
Pathologic complete response rate was defined as percentage of participants with pathologic complete response. Pathologic complete response rate following triplet therapy (enzalutamide in combination with leuprolide and dutasteride) and enzalutamide alone when administered as neoadjuvant therapy for 180 days prior to prostatectomy in participants with localized prostate cancer. Pathologic complete response was defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen, as assessed by the local and central pathologist.
Time frame: Day 180
Percentage of Participants With Positive Surgical Margins
To determine the percentage of participants with positive surgical margins at prostatectomy as assessed by the local and central pathologist. Surgical margin, also known as tumor free margin referred to the visible normal tissue or skin margin that was removed with the surgical excision of a tumor, growth, or malignancy. The margin was described as positive when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed.
Time frame: Day 180
Percentage of Participants With Extracapsular Extension: Local Review
To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the local pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.
Time frame: Day 180
Percentage of Participants With Extracapsular Extension: Central Review
To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the central pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.
Time frame: Day 180
Percentage of Participants With Positive Seminal Vesicles
To determine the percentage of participants with positive seminal vesicles at prostatectomy as assessed by the local and central pathologist. Seminal vesicles or seminal glands, were defined as a pair of simple tubular glands located within the pelvis. They secrete fluid that partly composes the semen. Seminal vesicles with cancer cells in them were called positive seminal vesicles.
Time frame: Day 180
Percentage of Participants With Positive Lymph Nodes
To determine the percentage of participants with positive lymph nodes at prostatectomy as assessed by the local and central pathologist. Lymph nodes were small clumps of immune cells that act as filters for the lymphatic system. Lymph nodes with cancer cells in them were called positive lymph nodes.
Time frame: Day 180
Prostate-Specific Antigen (PSA) Nadir
To determine the effects on PSA as measured by the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.
Time frame: Day 195
Time to Prostate-Specific Antigen (PSA) Nadir
To determine the effects on PSA as measured by the time to the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.
Time frame: Day 195
Percentage of Participants With Reduction in Prostate-Specific Antigen (PSA)
To determine the effects on PSA as measured by the percentage of participants with PSA less than (\<) 0.2 nanogram per milliliter (ng/mL), and a 50 percent (%) and 90% decrease in PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland.
Time frame: Day 195
Health-Related Quality of Life (HRQoL): Number of Participants With The Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain Summary Score
EPIC sexual domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. Sexual domain summary score was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function and satisfaction. Best change from baseline category in EPIC sexual domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Function Subscale Score
EPIC sexual function subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual function subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function. Best change from baseline category in EPIC sexual function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Sexual Bother Subscale Score
EPIC sexual bother subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual bother subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing less sexual bother and difficulty. Best change from baseline category in EPIC sexual bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Domain Summary Score
EPIC Hormonal Domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Function Subscale Score
EPIC hormonal function subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal function subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Expanded Prostate Cancer Index Composite (EPIC) Hormonal Bother Subscale Score
EPIC hormonal bother subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal bother subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing less hormonal bothering. Best change from baseline category in EPIC hormonal bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 General Health Domain Score
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The general health domain score contained 1 item scored on a scale of 1 to 5 where 1=excellent to 5=poor health, where higher score indicated worse health status. Best change from baseline category in general health domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Physical Functioning Domain Score
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The physical functioning domain score contained 2 items each scored on a scale of 1 to 5 where 1=excellent physical functioning to 5=poor physical functioning. Physical functioning domain total score ranged from 1 to 10, where higher scores indicated poor physical functioning. Best change from baseline category in physical functioning domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Role-Emotional Domain Score
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5, where higher scores indicated worse mental status. The total score ranged from 1 to 10, where higher scores indicated worse mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
Time frame: Day 180
Health-Related Quality of Life (HRQoL): Number of Participants With Twelve-Item Short Form Version 2 Mental Component Summary
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5 where for 1 item 1=all of the time person felt calm and peaceful to 5=none of the time person felt calm and peaceful. The score ranged from 1 to 5, where higher scores meant worse mental status. For other item 1=all of the time person felt downhearted and blue to 5=none of the time person felt downhearted and blue. The score ranged from 1 to 5, where higher scores meant better mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
Time frame: Day 180
Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT)
To determine pharmacodynamic effects as measured by the amount of tissue DHT in prostatectomy specimens following radical prostatectomy.
Time frame: Day 180
Pharmacodynamic Effects: Tissue Testosterone
To determine pharmacodynamic effects as measured by the amount of tissue testosterone in prostatectomy specimens following radical prostatectomy.
Time frame: Day 180
Pharmacodynamic Effects: Assessment of Apoptosis
To determine the effects of triplet therapy and enzalutamide alone on apoptosis in prostatectomy specimens. Apoptosis was a process of biochemical events that lead to characteristic cell changes and death.
Time frame: Day 180
Pharmacodynamic Effects: Assessment of Mitotic Index
Assessment was performed to determine the effects of triplet therapy and enzalutamide alone on mitotic index. Mitotic index was defined as the ratio between the numbers of cells in a population undergoing mitosis to the number of cells in a population not undergoing mitosis in prostatectomy specimens.
Time frame: Day 180
Pharmacodynamic Effects: Assessment of Androgen Receptor Signaling as Measured by Intensity of Androgen Receptor Immunohistochemical (IHC) Staining
To determine the effects of triplet therapy and enzalutamide alone on androgen receptor signaling in prostatectomy specimens. Androgen receptor (AR) was a type of nuclear receptor that was activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. Androgen receptor (AR) signaling represented the major therapeutic target for treating metastatic prostate cancer. Assessment of androgen receptor signaling was measured by intensity of androgen receptor IHC staining and were graded as 0 (absent), 1 (weak), 2 (moderate) and 3 (strong). Percentage of participants within each grade are reported below.
Time frame: Day 180
Serum Dihydrotestosterone (DHT): Baseline
Time frame: Baseline
Serum Dihydrotestosterone (DHT): Day 180
Time frame: Day 180
Change From Baseline in Serum Dihydrotestosterone (DHT) at Day 180
To determine serum hormone effects as measured by change in DHT values from baseline to the completion of therapy.
Time frame: Day 180
Serum Testosterone: Baseline
Time frame: Baseline
Serum Testosterone: Day 180
Time frame: Day 180
Change From Baseline in Serum Testosterone at Day 180
To determine serum hormone effects as measured by change in testosterone at baseline and at completion of therapy.
Time frame: Day 180
Number of Participants With Adverse Events (AEs) That Led to Dose Interruption, Dose Reduction, and Study Drug Discontinuation
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Time frame: From baseline up to 210 days
| Milestone | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Started | 25 | 27 |
| Completed | 23 | 25 |
| Not completed | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 |
Pathologic complete response rate was defined as percentage of participants with pathologic complete response. Pathologic complete response rate following triplet therapy (enzalutamide in combination with leuprolide and dutasteride) and enzalutamide alone when administered as neoadjuvant therapy for 180 days prior to prostatectomy in participants with localized prostate cancer. Pathologic complete response was defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen, as assessed by the local and central pathologist.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Local pathologist | 8.7 (1.1 to 28.0) | 0.0 (0.0 to 13.7) |
| Central pathologist | 4.3 (0.1 to 21.9) | 0.0 (0.0 to 13.7) |
To determine the percentage of participants with positive surgical margins at prostatectomy as assessed by the local and central pathologist. Surgical margin, also known as tumor free margin referred to the visible normal tissue or skin margin that was removed with the surgical excision of a tumor, growth, or malignancy. The margin was described as positive when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Local pathologist | 4.3 (0.1 to 21.9) | 12.0 (2.5 to 31.2) |
| Central pathologist | 21.7 (7.5 to 43.7) | 16.0 (4.5 to 36.1) |
To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the local pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Percentage of Participants With Extracapsular Extension: Local Review | 26.1 (10.2 to 48.4) | 36.0 (18.0 to 57.5) |
To determine the percentage of participants with extracapsular extension at prostatectomy as assessed by the central pathologist. Extracapsular extension was defined as prostate cancer cells when extended into the prostate capsule or outer lining of the prostate gland.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Percentage of Participants With Extracapsular Extension: Central Review | 56.5 (34.5 to 76.8) | 70.8 (48.9 to 87.4) |
To determine the percentage of participants with positive seminal vesicles at prostatectomy as assessed by the local and central pathologist. Seminal vesicles or seminal glands, were defined as a pair of simple tubular glands located within the pelvis. They secrete fluid that partly composes the semen. Seminal vesicles with cancer cells in them were called positive seminal vesicles.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Local pathologist | 30.4 (13.2 to 52.9) | 36.0 (18.0 to 57.5) |
| Central pathologist | 30.4 (13.2 to 52.9) | 36.0 (18.0 to 57.5) |
To determine the percentage of participants with positive lymph nodes at prostatectomy as assessed by the local and central pathologist. Lymph nodes were small clumps of immune cells that act as filters for the lymphatic system. Lymph nodes with cancer cells in them were called positive lymph nodes.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Local pathologist | 26.1 (10.2 to 48.4) | 4.0 (0.1 to 20.4) |
| Central pathologist | 26.1 (10.2 to 48.4) | 4.0 (0.1 to 20.4) |
To determine the effects on PSA as measured by the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.
| microgram per liter (mcg/L) | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Prostate-Specific Antigen (PSA) Nadir | 0.04 (0.01 to 0.53) | 0.51 (0.02 to 8.80) |
To determine the effects on PSA as measured by the time to the lowest post baseline PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA nadir was the participant's lowest observed post baseline PSA value.
| days | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Time to Prostate-Specific Antigen (PSA) Nadir | 5.09 (2.79 to 6.44) | 6.01 (2.89 to 6.64) |
To determine the effects on PSA as measured by the percentage of participants with PSA less than (\<) 0.2 nanogram per milliliter (ng/mL), and a 50 percent (%) and 90% decrease in PSA value prior to prostatectomy. Prostate-specific antigen (PSA) was a protein produced by normal, as well as malignant, cells of the prostate gland.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| PSA < 0.2 ng/mL | 92.0 (74.0 to 99.0) | 29.6 (13.8 to 50.2) |
| 50% decrease in PSA | 100.0 (86.3 to 100.0) | 100.0 (87.2 to 100.0) |
| 90% decrease in PSA | 100.0 (86.3 to 100.0) | 63.0 (42.4 to 80.6) |
EPIC sexual domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. Sexual domain summary score was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function and satisfaction. Best change from baseline category in EPIC sexual domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 11 | 10 |
| Stable | 4 | 6 |
| Improved | 1 | 0 |
EPIC sexual function subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual function subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing better sexual function. Best change from baseline category in EPIC sexual function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 11 | 12 |
| Stable | 4 | 5 |
| Improved | 0 | 0 |
EPIC sexual bother subscale was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's sexual function and sexual satisfaction. EPIC sexual bother subscale was a component of sexual domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) with higher scores representing less sexual bother and difficulty. Best change from baseline category in EPIC sexual bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation of baseline score. Number of participants within each category are reported below.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 7 | 5 |
| Stable | 9 | 7 |
| Improved | 0 | 4 |
EPIC Hormonal Domain was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal domain summary score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 10 | 10 |
| Stable | 3 | 7 |
| Improved | 3 | 1 |
EPIC hormonal function subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal function subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing better hormonal function. Best change from baseline category in EPIC hormonal function subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 11 | 11 |
| Stable | 2 | 7 |
| Improved | 3 | 0 |
EPIC hormonal bother subscale score was HRQoL instrument that measured the effects of prostate cancer treatment on a participant's hormonal function. EPIC hormonal bother subscale was a component of hormonal domain that was evaluated on a distinct set of questions. It was measured on a scale ranged from 0 (worst) to 100 (best) scale with higher scores representing less hormonal bothering. Best change from baseline category in EPIC hormonal bother subscale score ranged from worsened to improved where worsened indicated decrease of at least 1 minimally important difference, stable indicated changed by less than 1 minimally important difference and improved indicated increase of at least 1 minimally important difference. Minimally important difference was defined as one-half of the standard deviation baseline score. Number of participants within each category are reported below.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 9 | 6 |
| Stable | 5 | 11 |
| Improved | 2 | 1 |
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The general health domain score contained 1 item scored on a scale of 1 to 5 where 1=excellent to 5=poor health, where higher score indicated worse health status. Best change from baseline category in general health domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 5 | 5 |
| Stable | 9 | 6 |
| Improved | 2 | 7 |
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The physical functioning domain score contained 2 items each scored on a scale of 1 to 5 where 1=excellent physical functioning to 5=poor physical functioning. Physical functioning domain total score ranged from 1 to 10, where higher scores indicated poor physical functioning. Best change from baseline category in physical functioning domain score ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 3 | 2 |
| Stable | 12 | 15 |
| Improved | 1 | 1 |
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5, where higher scores indicated worse mental status. The total score ranged from 1 to 10, where higher scores indicated worse mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 3 | 1 |
| Stable | 9 | 10 |
| Improved | 4 | 7 |
The Twelve-Item Short Form Version 2 was HRQoL instrument that measured general health and well-being across physical and mental components. The mental health domain score had 2 items scored on a scale of 1 to 5 where for 1 item 1=all of the time person felt calm and peaceful to 5=none of the time person felt calm and peaceful. The score ranged from 1 to 5, where higher scores meant worse mental status. For other item 1=all of the time person felt downhearted and blue to 5=none of the time person felt downhearted and blue. The score ranged from 1 to 5, where higher scores meant better mental status. Best change from baseline category in mental component summary ranged from worsened (decrease of at least 1 minimally important difference), stable (changed by less than 1 minimally important difference), or improved (increase of at least 1 minimally important difference). Minimally important difference was defined as one-half the standard deviation of the score of interest at baseline.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Worsened | 4 | 1 |
| Stable | 8 | 11 |
| Improved | 4 | 5 |
To determine pharmacodynamic effects as measured by the amount of tissue DHT in prostatectomy specimens following radical prostatectomy.
| picogram per milligram | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Pharmacodynamic Effects: Tissue Dihydrotestosterone (DHT) | 0.04 ± 0.01 | 3.34 ± 1.57 |
To determine pharmacodynamic effects as measured by the amount of tissue testosterone in prostatectomy specimens following radical prostatectomy.
| picogram per milligram | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Pharmacodynamic Effects: Tissue Testosterone | 0.18 ± 0.13 | 0.90 ± 0.86 |
To determine the effects of triplet therapy and enzalutamide alone on apoptosis in prostatectomy specimens. Apoptosis was a process of biochemical events that lead to characteristic cell changes and death.
No measurements were reported for this outcome.
Assessment was performed to determine the effects of triplet therapy and enzalutamide alone on mitotic index. Mitotic index was defined as the ratio between the numbers of cells in a population undergoing mitosis to the number of cells in a population not undergoing mitosis in prostatectomy specimens.
| ratio | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Pharmacodynamic Effects: Assessment of Mitotic Index | 0.9 ± 1.51 | 2.6 ± 2.81 |
To determine the effects of triplet therapy and enzalutamide alone on androgen receptor signaling in prostatectomy specimens. Androgen receptor (AR) was a type of nuclear receptor that was activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. Androgen receptor (AR) signaling represented the major therapeutic target for treating metastatic prostate cancer. Assessment of androgen receptor signaling was measured by intensity of androgen receptor IHC staining and were graded as 0 (absent), 1 (weak), 2 (moderate) and 3 (strong). Percentage of participants within each grade are reported below.
| percentage of participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| 0 | 0.0 | 0.0 |
| 1 | 5.6 | 0.0 |
| 2 | 27.8 | 5.3 |
| 3 | 66.7 | 94.7 |
| ng/mL | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Serum Dihydrotestosterone (DHT): Baseline | 0.34 (0.08 to 0.58) | 0.29 (0.16 to 0.85) |
| ng/mL | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Serum Dihydrotestosterone (DHT): Day 180 | 0.01 (0.01 to 0.04) | 0.51 (0.10 to 1.10) |
To determine serum hormone effects as measured by change in DHT values from baseline to the completion of therapy.
| ng/mL | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Change From Baseline in Serum Dihydrotestosterone (DHT) at Day 180 | -0.33 (-0.57 to -0.07) | 0.25 (-0.16 to 0.71) |
| ng/mL | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Serum Testosterone: Baseline | 4.10 (0.77 to 6.77) | 3.69 (2.00 to 7.91) |
| ng/mL | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Serum Testosterone: Day 180 | 0.12 (0.05 to 0.29) | 9.76 (1.99 to 16.63) |
To determine serum hormone effects as measured by change in testosterone at baseline and at completion of therapy.
| ng/mL | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Change From Baseline in Serum Testosterone at Day 180 | -4.00 (-6.67 to -0.67) | 5.74 (-1.94 to 12.29) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
| participants | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Permanent Discontinuation of Enzalutamide | 0 | 0 |
| Temporary Interruption of Enzalutamide | 3 | 0 |
| Dose Reduction of Enzalutamide | 0 | 0 |
| Study Drug Discontinuation | 0 | 0 |
Collected over From baseline to 30 days after the last dose of study drug, up to 210 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide + Leuprolide + Dutasteride | — | 3/25 (12%) | 25/25 (100%) |
| Enzalutamide | — | 2/27 (7.4%) | 27/27 (100%) |
| Event | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Postoperative ileusInjury, poisoning and procedural complications | 1/25 | 0/27 |
| Clostridial infectionInfections and infestations | 1/25 | 0/27 |
| LymphoceleVascular disorders | 1/25 | 1/27 |
| Pelvic abscessInfections and infestations | 0/25 | 1/27 |
| Event | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide |
|---|---|---|
| Hot flushVascular disorders | 24/25 | 7/27 |
| FatigueGeneral disorders | 15/25 | 19/27 |
| GynaecomastiaReproductive system and breast disorders | 3/25 | 17/27 |
| InsomniaPsychiatric disorders | 9/25 | 6/27 |
| Breast tendernessReproductive system and breast disorders | 2/25 | 9/27 |
| Libido decreasedPsychiatric disorders | 8/25 | 4/27 |
| Breast painReproductive system and breast disorders | 0/25 | 7/27 |
| DiarrhoeaGastrointestinal disorders | 6/25 | 5/27 |
| PollakiuriaRenal and urinary disorders | 6/25 | 4/27 |
| Erectile dysfunctionReproductive system and breast disorders | 2/25 | 6/27 |
| Age, Continuous(years) | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide | Total |
|---|---|---|---|
| Mean | 60.8 ± 6.95 | 61.4 ± 7.65 | 61.1 ± 7.26 |
| Sex: Female, Male(Participants) | Enzalutamide + Leuprolide + Dutasteride | Enzalutamide | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 25 | 27 | 52 |
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
No publications or documents are linked to this record.
Ran from Mar 2012 to primary completion in Nov 2013, 19 months.
Results were first posted in Apr 2015, 1 year 4 months after primary completion. A results delay was requested in Dec 2014.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 19 months is below that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide